Search

Your search keyword '"Drummond, Mark"' showing total 650 results
Start Over Author "Drummond, Mark"
650 results on '"Drummond, Mark"'

4. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

Author

Rodriguez-Meira, Alba, Norfo, Ruggiero, Wen, Sean, Chédeville, Agathe L., Rahman, Haseeb, O’Sullivan, Jennifer, Wang, Guanlin, Louka, Eleni, Kretzschmar, Warren W., Paterson, Aimee, Brierley, Charlotte, Martin, Jean-Edouard, Demeule, Caroline, Bashton, Matthew, Sousos, Nikolaos, Moralli, Daniela, Subha Meem, Lamia, Carrelha, Joana, Wu, Bishan, Hamblin, Angela, Guermouche, Helene, Pasquier, Florence, Marzac, Christophe, Girodon, François, Vainchenker, William, Drummond, Mark, Harrison, Claire, Chapman, J. Ross, Plo, Isabelle, Jacobsen, Sten Eirik W., Psaila, Bethan, Thongjuea, Supat, Antony-Debré, Iléana, and Mead, Adam J.

Published
2023
Full Text
View/download PDF

6. Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis

Author

Fang, Zijian, Corbizi Fattori, Giuditta, McKerrell, Thomas, Boucher, Rebecca H., Jackson, Aimee, Fletcher, Rachel S., Forte, Dorian, Martin, Jose-Ezequiel, Fox, Sonia, Roberts, James, Glover, Rachel, Harris, Erica, Bridges, Hannah R., Grassi, Luigi, Rodriguez-Meira, Alba, Mead, Adam J., Knapper, Steven, Ewing, Joanne, Butt, Nauman M., Jain, Manish, Francis, Sebastian, Clark, Fiona J., Coppell, Jason, McMullin, Mary F., Wadelin, Frances, Narayanan, Srinivasan, Milojkovic, Dragana, Drummond, Mark W., Sekhar, Mallika, ElDaly, Hesham, Hirst, Judy, Paramor, Maike, Baxter, E. Joanna, Godfrey, Anna L., Harrison, Claire N., and Méndez-Ferrer, Simón

Published
2023
Full Text
View/download PDF

7. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

Author

DeAngelo, Daniel J., Radia, Deepti H., George, Tracy I., Robinson, William A., Quiery, Albert T., Drummond, Mark W., and Bose, Prithviraj

Subjects
Mast cell disease -- Diagnosis -- Care and treatment -- Risk factors, Biological sciences, Health
Abstract

Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients with AdvSM. The primary endpoints were the maximum tolerated dose, recommended phase 2 dose and safety of avapritinib. Secondary endpoints included overall response rate and changes in measures of mast cell burden. Avapritinib was evaluated at doses of 30-400 mg once daily in 86 patients, 69 with centrally confirmed AdvSM. Maximum tolerated dose was not reached, and 200 mg and 300 mg daily were studied in dose-expansion cohorts. The most frequent adverse events observed were periorbital edema (69%), anemia (55%), diarrhea (45%), thrombocytopenia (44%) and nausea (44%). Intracranial bleeding occurred in 13% overall, but in only 1% of patients without severe thrombocytopenia (platelets In a phase 1 trial of patients with advanced systemic mastocytosis, avapritinib, a selective KIT inhibitor, was generally well tolerated, elicited durable clinical responses and led to reductions in mast cell disease burden., Author(s): Daniel J. DeAngelo [sup.1] , Deepti H. Radia [sup.2] , Tracy I. George [sup.3] , William A. Robinson [sup.4] , Albert T. Quiery [sup.5] , Mark W. Drummond [sup.6] [...]

Published
2021
Full Text
View/download PDF

8. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆

Author

Yee, Karen, Papayannidis, Cristina, Vey, Norbert, Dickinson, Michael J., Kelly, Kevin R., Assouline, Sarit, Kasner, Margaret, Seiter, Karen, Drummond, Mark W., Yoon, Sung-Soo, Lee, Je-Hwan, Blotner, Steven, Jukofsky, Lori, Pierceall, William E., Zhi, Jianguo, Simon, Silke, Higgins, Brian, Nichols, Gwen, Monnet, Annabelle, Muehlbauer, Susanne, Ott, Marion, Chen, Lin-Chi, and Martinelli, Giovanni

Published
2021
Full Text
View/download PDF

9. Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A

Author

Brierley, Charlotte K, primary, Yip, Bon Ham, additional, Orlando, Giulia, additional, Goyal, Harsh, additional, Wen, Sean, additional, Wen, Jeremy, additional, Levine, Max F, additional, Jakobsdottir, Maria G, additional, Rodriguez-Meira, Alba, additional, Adamo, Assunta, additional, Bashton, Matthew, additional, Hamblin, Angela, additional, Clark, Sally A, additional, O'Sullivan, Jennifer, additional, Murphi, Lauren, additional, Olijnik-French, Aude-Anais, additional, Cotton, Anitria, additional, Narina, Shilpa, additional, Pruett-Miller, Shondra, additional, Enshaei, Amir, additional, Harrison, Claire, additional, Drummond, Mark, additional, Knapper, Stephen, additional, Tefferi, Ajalew, additional, Antony-Debre, Ileana, additional, Thongjuea, Supat, additional, Wedge, David C, additional, Constantinescu, Stefan, additional, Papaemmanuil, Elli, additional, Psaila, Bethan, additional, Crispino, John D, additional, and Mead, Adam J, additional

Published
2023
Full Text
View/download PDF

11. Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study.

Author

Sarocchi, Matteo, Li, Junmin, Li, Xiao, Wu, Depei, Montaño Figueroa, Efreen, Rodriguez, Maria Guadalupe, Hou, Ming, Finelli, Carlo, Shi, Hong‐Xia, Xiao, Zhijian, Oliva, Esther Natalie, Gercheva Kyuchukova, Liana, Drummond, Mark, Symeonidis, Argiris, Velazquez, Eric J., Rivoli, Giulia, Izquierdo, Miguel, Kolekar, Yogita, Spallarossa, Paolo, and Angelucci, Emanuele

Subjects
MYELODYSPLASTIC syndromes, IRON overload, FETOFETAL transfusion, DEFERASIROX, CONGESTIVE heart failure, IRON chelates, DIASTOLE (Cardiac cycle)
Abstract

Summary: Iron overload from repeated transfusions has a negative impact on cardiac function, and iron chelation therapy may help prevent cardiac dysfunction in transfusion‐dependent patients with myelodysplastic syndromes (MDS). TELESTO (NCT00940602) was a prospective, placebo‐controlled, randomised study to evaluate the iron chelator deferasirox in patients with low‐ or intermediate‐1–risk MDS and iron overload. Echocardiographic parameters were collected at screening and during treatment. Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failure (CHF) or worsening of cardiac function (HR = 0.23; 95% CI: 0.05, 0.99; nominal p = 0.0322) versus placebo. No significant differences between the arms were found in left ventricular ejection fraction, ventricular diameter and mass or pulmonary artery pressure. The absolute number of events was low, but the enrolled patients were younger than average for patients with MDS, with no serious cardiac comorbidities and a modest cardiovascular risk profile. These results support the effectiveness of deferasirox in preventing cardiac damage caused by iron overload in this patient population. Identification of patients developing CHF is challenging due to the lack of distinctive echocardiographic features. The treatment of iron overload may be important to prevent cardiac dysfunction in these patients, even those with moderate CHF risk. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Spectroscopy of ¹⁶³,¹⁶⁵Os and ¹⁶⁴Ir

Author

Drummond, Mark Christopher, Page, Robert, and Chartier, Marielle

Subjects
530, QC Physics
Abstract

Excited states in the neutron-deficient isotopes ¹⁶³Os and ¹⁶⁵Os were identified using Jurogam and GREAT spectrometers in conjunction with the RITU gas-filled separator. The ¹⁶³Os and ¹⁶⁵Os nuclei were populated via the ¹⁰⁶Cd⁶⁰(Ni,3n) and ⁹²Mo(⁷⁸Kr,2p3n) reactions at bombarding energies of 270 MeV and 357 MeV, respectively. Gamma-ray emissions from these nuclei have been established unambiguously using the recoil-decay tagging technique and a coincidence analysis has allowed level schemes to be established. These results suggest that the yrast states are based upon negative-parity configurations originating from the νf⁷/₂ and νh⁹/₂ orbitals. The neutron deficient odd-odd nucleus ¹⁶⁴Ir has been studied using the GREAT spectrometer in conjunction with the RITU gas-filled separator. The experiment was performed using the ⁹²Mo(⁷⁸Kr, p5n)¹⁶⁴Ir reaction at bombarding energies of 420-450 MeV for 12 days. An alpha decay has been observed for the first time with an energy of 6880 ± 10 keV and a branching ratio of 4.8 ± 2.2 % and assigned as the decay of the πh¹¹/₂ state of ¹⁶⁴Ir. The energy of the proton decay of the high-spin state has been measured to a higher precision as 1814 ± 6 keV. The half life of this state has been measured to be 70 ± 10 μs. The DSSDs of the GREAT spectrometer have been instrumented using digital electronics for the first time and a pulse shape analysis has been performed to observe particle emission within the dead time of the detector.

Published
2013
Full Text
View/download PDF

16. RETIREMENT: A Year in Review.

Author

Drummond, Mark A.

Subjects
Retired judges -- Management -- Social aspects, Pro bono legal services -- Influence -- Management, Company business management
Abstract

You know, I really should write all of this down," I remarked to my wife, Carol, as I stared into the box of vegetables while holding what I later learned [...]

Published
2020

18. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Author

Harrison, Claire N., primary, Nangalia, Jyoti, additional, Boucher, Rebecca, additional, Jackson, Aimee, additional, Yap, Christina, additional, O'Sullivan, Jennifer, additional, Fox, Sonia, additional, Ailts, Isaak, additional, Dueck, Amylou C., additional, Geyer, Holly L., additional, Mesa, Ruben A., additional, Dunn, William G., additional, Nadezhdin, Eugene, additional, Curto-Garcia, Natalia, additional, Green, Anna, additional, Wilkins, Bridget, additional, Coppell, Jason, additional, Laurie, John, additional, Garg, Mamta, additional, Ewing, Joanne, additional, Knapper, Steven, additional, Crowe, Josephine, additional, Chen, Frederick, additional, Koutsavlis, Ioannis, additional, Godfrey, Anna, additional, Arami, Siamak, additional, Drummond, Mark, additional, Byrne, Jennifer, additional, Clark, Fiona, additional, Mead-Harvey, Carolyn, additional, Baxter, Elizabeth Joanna, additional, McMullin, Mary Frances, additional, and Mead, Adam J., additional

Published
2023
Full Text
View/download PDF

20. Telomere dynamics and telomerase expression in chronic myeloid leukaemia

Author

Drummond, Mark William

Subjects
616.99419
Abstract

INTRODUCTION: Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of the haemopoietic stem cell (HSC), with a variable clinical course. Chronic phase (CP) disease, typically of 4-5 years duration, progresses to accelerated (AP) and then blastic phase (BP), with the latter behaving as a particularly aggressive acute leukaemia of either myeloid (MBP) or lymphoid (LBP) lineage. Treatment is most successful when delivered in CP, and accurate prognostic indices are required to individualise treatment. Increased telomere shortening has been described during progression of CML, and may be of prognostic relevance. Paradoxically, telomerase activity (TA, as determined by the TRAP assay) has been shown to be elevated in the CP stem/progenitor cell (CD34+) compartment: however this may not accurately reflect telomere maintenance in-vivo. We sought to further define the prognostic significance of telomere shortening at diagnosis of CML, monitor the rate of telomere loss during the disease and characterise expression of the major telomerase components (hTR and hTERT) in CD34+ selected cells at diagnosis and during disease progression. METHODS: Peripheral blood leucocyte (PBL) telomere length measurement was performed by flow-FISH on cohorts of normal individuals, patients at diagnosis and all stages of CML. To define the degree of telomere shortening in individual patients at diagnosis ex-vivo expanded (BCR-ABL') T-cells were used as an internal control for 'normal' somatic cell telomere length. Expression of hTERT and hTR was quantified by Q RT-PCR and hTERT mRNA splice variants detected by RT-PCR. CD34+ selected cells from CML patients were confirmed as BCR-ABL+ by FISH. TA was determined by TRAP assay. RESULTS: Telomere shortening in CP and AP CIVIL patients progressed at 10-20 times the rate of age-related shortening observed in the normal control group. Furthermore, high-risk prognostic score patients at diagnosis had significantly shorter telomeres than low-risk patients. High purity CD34+ selected cells from CML, as compared to normal, demonstrated increased TRAP activity which correlated with the proportion of cycling cells. However, hTERT mRNA expression was not significantly elevated. Unexpectedly, Q-RT-PCR for hTR demonstrated a mean five-fold reduction in levels in the CML samples, raising the possibility that telomere homeostasis is disrupted in CML. In BP samples, hTERT expression was significantly lower in MBP than LBP and this was mirrored by a corresponding shift in hTERT splicing patterns. MBP hTERT expression correlated inversely with telomere length. CONCLUSIONS; In summary, increased TRAP activity is not synonymous with telomere maintenance in CML, and dysregulated expression of hTR may contribute to the telomere loss observed in these patients. Indeed TRAP activity appeared largely dependent on the proportion of cycling cells. In the context of progressive (i.e. BP) disease, hTERT expression is lineage and telomere length dependent, thus explaining inconsistent reports of TA levels in BP samples. We have also demonstrated that subtle shifts in splicing of hTERT mRNA is likely to have a regulatory role in primary HSC. In prognostic terms telomere shortening in CML is greatest in high-risk score patients at diagnosis, and occurs rapidly during disease progression. These data further emphasise the potential clinical utility of telomere length measurement for prognostic modelling and monitoring of disease progression.

Published
2003
Full Text
View/download PDF

21. Supplemental Figures 1 and 2 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

22. Supplemental Methods from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

23. Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

24. Data from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

25. Tamoxifen reduces mitochondrial respiration, oncogenic signaling and mutant allele burden in a myeloproliferative neoplasm subset

Author

Fang, Zijian, primary, Fattori, Giuditta, additional, McKerrell, Thomas, additional, Boucher, Rebecca, additional, Jackson, Aimee, additional, Fletcher, Rachel, additional, Forte, Dorian, additional, Martin, Jose-Ezequiel, additional, Fox, Sonia, additional, Roberts, James, additional, Glover, Rachel, additional, Harris, Erica, additional, Bridges, Hannah, additional, Grassi, Luigi, additional, Rodriguez-Meira, Alba, additional, Mead, Adam, additional, Knapper, Steven, additional, Ewing, Joanne, additional, Butt, Nauman, additional, Jain, Manish, additional, Francis, Sebastian, additional, Clark, Fiona, additional, Coppell, Jason, additional, McMullin, Mary, additional, Wadelin, Frances, additional, Narayanan, Srinivasan, additional, Milojkovic, Dragana, additional, Drummond, Mark, additional, Sekhar, Mallika, additional, ElDaly, Hesham, additional, Hirst, Judy, additional, Paramor, Maike, additional, Baxter, Elizabeth, additional, Godfrey, Anna, additional, Harrison, Claire, additional, and Mendez-Ferrer, Simon, additional

Published
2023
Full Text
View/download PDF

26. 3031 – CHROMOTHRIPSIS AND LEUKEMIC TRANSFORMATION IN MPN

Author

Brierley, Charlotte, primary, Yip, Bon Ham, additional, Orlando, Giulia, additional, Goyal, Harsh, additional, Wen, Sean, additional, Wen, Jeremy, additional, Levine, Max, additional, Rodriguez-Meira, Alba, additional, Adamo, Assunta, additional, Bashton, Matthew, additional, Hamblin, Angela, additional, Clark, Sally Ann, additional, Fletcher, Rachel, additional, Fox, Sonia, additional, Gaskell, Charlotte, additional, O'Sullivan, Jennifer, additional, Murphy, Lauren, additional, Sousos, Nikolaos, additional, Enshai, Amir, additional, Harrison, Claire, additional, Drummond, Mark, additional, Knapper, Steven, additional, Antony-Debre, Ileana, additional, Thongjuea, Supat, additional, Constantinescu, Stefan, additional, Papaemmanuil, Elli, additional, Psaila, Bethan, additional, Crispino, John, additional, and Mead, Adam, additional

Published
2023
Full Text
View/download PDF

28. 1948. Evaluation of a heterologous booster vaccine regimen: Pfizer-BioNTech BNT162b2 mRNA booster vaccine following priming with Novavax NVX-CoV2373

Author

Babu, Tara M, primary, Scott McClelland, R, additional, Johnston, Christine, additional, Selke, Stacy, additional, Singh, Dilpreet, additional, Moreno, Jessica, additional, Taub, Jina, additional, Pertik, Morissa, additional, Varon, Dana, additional, Pholsena, Thepthara, additional, Murphy, Britt, additional, Drummond, Mark, additional, McClellan, Lindsey, additional, Braun, Alyssa, additional, Seymour, Matthew, additional, Hauge, Kirsten, additional, McClurkan, Chris L, additional, Wilkens, Chloe, additional, Goecker, Erin, additional, Laing, Kerry J, additional, Koelle, David M, additional, Greninger, Alexander L, additional, and Wald, Anna, additional

Published
2022
Full Text
View/download PDF

29. The Changing Southwest

Author

Theobald, David M., Travis, William R., Drummond, Mark A., Gordon, Eric S., Betsill, Michele, Garfin, Gregg, editor, Jardine, Angela, editor, Merideth, Robert, editor, Black, Mary, editor, and LeRoy, Sarah, editor

Published
2013
Full Text
View/download PDF

30. Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

Author

Radia, Deepti H., primary, Gotlib, Jason, additional, Drummond, Mark W., additional, George, Tracy I., additional, Lin, Hui-Min, additional, Dimitrijević, Saša, additional, Munoz-Gonzalez, Javier I., additional, Bidollari, Ilda, additional, Deininger, Michael W., additional, DeAngelo, Daniel J., additional, and Reiter, Andreas, additional

Published
2022
Full Text
View/download PDF

31. An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

Author

DeAngelo, Daniel J., primary, Radia, Deepti H., additional, George, Tracy I., additional, Robinson, William A., additional, Quiery, Albert T., additional, Drummond, Mark W., additional, Bose, Prithviraj, additional, Hexner, Elizabeth O., additional, Winton, Elliott, additional, Horny, Hans-Peter, additional, Tugnait, Meera, additional, Lin, Hui-Min, additional, Dimitrijević, Saša, additional, Munoz-Gonzalez, Javier I., additional, Bidollari, Ilda, additional, Deininger, Michael W., additional, and Gotlib, Jason, additional

Published
2022
Full Text
View/download PDF

32. Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Author

Harrison, Claire, primary, Nangalia, Jyoti, additional, Boucher, Rebecca H., additional, Jackson, Aimee, additional, Yap, Christina, additional, O'Sullivan, Jennifer, additional, Fox, Sonia, additional, Ailts, Isaak, additional, Dueck, Amylou C, additional, Geyer, Holly L., additional, Mesa, Ruben, additional, Dunn, William, additional, Nadezhdin, Eugene, additional, Curto-Garcia, Natalia, additional, Green, Anna, additional, Wilkins, Bridget, additional, Coppell, Jason, additional, Laurie, John, additional, Garg, Mamta, additional, Ewing, Joanne, additional, Knapper, Steve, additional, Crowe, Josephine, additional, Koutsavlis, Ioannis, additional, Godfrey, Anna L, additional, Arami, Siamak, additional, Drummond, Mark W., additional, Byrne, Jennifer, additional, Clark, Fiona J, additional, Mead-Harvey, Carolyn, additional, Baxter, Joanna E, additional, McMullin, Mary Frances, additional, and Mead, Adam J, additional

Published
2022
Full Text
View/download PDF

33. Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK

Author

Carpenter, Lewis, primary, Rockenschaub, Patrick, additional, Hatton, Grace B., additional, D'Abrantes, Sofia, additional, Sims, Edward, additional, Scott‐Ram, Nicholas, additional, Ducès, Aurélie, additional, Emanuel, Gabrielle, additional, Mead, Adam J., additional, Drummond, Mark W., additional, and Lipunova, Nadezda, additional

Published
2022
Full Text
View/download PDF

39. Deciphering TP53 mutant Cancer Evolution with Single-Cell Multi-Omics

Author

Rodriguez-Meira, Alba, primary, Norfo, Ruggiero, additional, Wen, Wei Xiong, additional, Chédeville, Agathe L., additional, Rahman, Haseeb, additional, O’Sullivan, Jennifer, additional, Wang, Guanlin, additional, Louka, Eleni, additional, Kretzschmar, Warren W., additional, Paterson, Aimee, additional, Brierley, Charlotte, additional, Martin, Jean-Edouard, additional, Demeule, Caroline, additional, Bashton, Matthew, additional, Sousos, Nikolaos, additional, Hamblin, Angela, additional, Guermouche, Helene, additional, Pasquier, Florence, additional, Marzac, Christophe, additional, Girodon, François, additional, Drummond, Mark, additional, Harrison, Claire, additional, Plo, Isabelle, additional, Jacobsen, Sten Eirik W., additional, Psaila, Bethan, additional, Thongjuea, Supat, additional, Antony-Debré, Iléana, additional, and Mead, Adam J, additional

Published
2022
Full Text
View/download PDF

41. 3170 – SINGLE-CELL MULTI-OMICS RESOLVES THE EVOLUTION OF TP53-MUTANT LEUKEMIA

Author

Rodriguez-Meira, Alba, primary, Norfo, Ruggiero, additional, Wen, Wei, additional, Chedeville, Agathe, additional, Rahman, Haseeb, additional, O'Sullivan, Jennifer, additional, Wang, Guanlin, additional, Louka, Eleni, additional, Kretzschmar, Warren, additional, Paterson, Aimee, additional, Brierley, Charlotte, additional, Martin, Jean-Edouard, additional, Demeule, Caroline, additional, Bashton, Matthew, additional, Sousos, Nikolaos, additional, Hamblin, Angela, additional, Guermouche, Helene, additional, Pasquier, Florence, additional, Marzac, Christophe, additional, Girodon, François, additional, Drummond, Mark, additional, Harrison, Claire, additional, Plo, Isabelle, additional, Jacobsen, Sten Eirik, additional, Psaila, Bethan, additional, Thongjuea, Supat, additional, Antony-Debré, Iléana, additional, and Mead, Adam, additional

Published
2022
Full Text
View/download PDF

43. Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Author

Saha, Chandan, primary, Mead-Harvey, Carolyn, additional, Mead, Adam J., additional, Boucher, Rebecca H., additional, Fox, Sonia, additional, Ailts, Isaak, additional, Yap, Christina, additional, Jackson, Aimee E, additional, Ewing, Joanne, additional, Coppell, Jason, additional, Knapper, Steve, additional, Drummond, Mark W., additional, Godfrey, Anna L, additional, Dueck, Amylou C., additional, Mesa, Ruben A., additional, Scherber, Robyn, additional, McMullin, Mary Frances, additional, Geyer, Holly L., additional, and Harrison, Claire N., additional

Published
2021
Full Text
View/download PDF

44. Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Author

Kremyanskaya, Marina, primary, Mascarenhas, John, additional, Palandri, Francesca, additional, Vannucchi, Alessandro, additional, Verstovsek, Srdan, additional, Harrison, Claire N., additional, Bose, Prithviraj, additional, Schiller, Gary J., additional, Rampal, Raajit, additional, Drummond, Mark W., additional, Gupta, Vikas, additional, Patriarca, Andrea, additional, Granacher, Nikki, additional, Scandura, Joseph, additional, Prejzner, Witold, additional, Teichmann, Lino L., additional, Curto-Garcia, Natalia, additional, Hoffman, Ronald, additional, Colak, Gozde, additional, Ren, Zheng, additional, Bobba, Suresh, additional, Cui, Jike, additional, Efuni, Sergey, additional, and Talpaz, Moshe, additional

Published
2021
Full Text
View/download PDF

45. Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Author

Ailts, Isaak, primary, Mead-Harvey, Carolyn, additional, Mead, Adam J., additional, Fox, Sonia, additional, Boucher, Rebecca H., additional, Yap, Christina, additional, Saha, Chandan, additional, Scherber, Robyn, additional, Jackson, Aimee, additional, Ewing, Joanne, additional, Coppell, Jason, additional, Knapper, Steve, additional, Drummond, Mark W., additional, Godfrey, Anna L, additional, Dueck, Amylou C., additional, McMullin, Mary Frances, additional, Mesa, Ruben A., additional, Harrison, Claire N., additional, and Geyer, Holly L., additional

Published
2021
Full Text
View/download PDF

46. Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN

Author

Rodriguez-Meira, Alba, primary, Rahman, Haseeb, additional, Norfo, Ruggiero, additional, Wen, Wei, additional, Chédeville, Agathe, additional, O'Sullivan, Jennifer, additional, Wang, Guanlin, additional, Paterson, Aimee, additional, Louka, Eleni, additional, Brierley, Charlotte K, additional, Kretzschmar, Warren W, additional, Girodon, Francois, additional, Ren, Zemin, additional, Bashton, Matthew, additional, Enshaei, Amir, additional, Drummond, Mark W., additional, Pasquier, Florence, additional, Marzac, Christophe, additional, Harrison, Claire N., additional, Plo, Isabelle, additional, Jacobsen, Sten Eirik W, additional, Thongjuea, Supat, additional, Psaila, Bethan, additional, Antony-Debre, Ileana, additional, and Mead, Adam J., additional

Published
2021
Full Text
View/download PDF

47. Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy

Author

Loke, Justin, primary, Metzner, Marlen, additional, Boucher, Rebecca, additional, Jackson, Aimee, additional, Hopkins, Louise, additional, Pavlu, Jiri, additional, Tholouli, Eleni, additional, Drummond, Mark, additional, Peniket, Andy, additional, Bishop, Rebecca, additional, Fox, Sonia, additional, Vyas, Paresh, additional, and Craddock, Charles, additional

Published
2021
Full Text
View/download PDF

48. MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study

Author

Bose, Prithviraj, primary, Verstovsek, Srdan, additional, Kremyanskaya, Marina, additional, Mascarenhas, John, additional, Talpaz, Moshe, additional, Harrison, Claire, additional, Rampai, Raajit, additional, Patriarca, Andrea, additional, Gupta, Vikas, additional, Granacher, Nikki, additional, Somervaille, Tim, additional, Schiller, Gary, additional, Drummond, Mark, additional, Foltz, Linda, additional, Lambert, Jonathan, additional, Prejzner, Witold, additional, Colak, Gozde, additional, Keller, Patricia, additional, Shao, James, additional, Luptakova, Katarina, additional, Hoffman, Ronald, additional, and Vannucchi, Alessandro, additional

Published
2021
Full Text
View/download PDF

49. Poster: MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study

Author

Bose, Prithviraj, primary, Verstovsek, Srdan, additional, Kremyanskaya, Marina, additional, Mascarenhas, John, additional, Talpaz, Moshe, additional, Harrison, Claire, additional, Rampal, Raajit, additional, Patriarca, Andrea, additional, Gupta, Vikas, additional, Granacher, Nikki, additional, Somervaille, Tim, additional, Schiller, Gary, additional, Drummond, Mark, additional, Foltz, Linda, additional, Lambert, Jonathan, additional, Prejzner, Witold, additional, Colak, Gozde, additional, Keller, Patricia, additional, Shao, James, additional, Luptakova, Katarina, additional, Hoffman, Ronald, additional, and Vannucchi, Alessandro, additional

Published
2021
Full Text
View/download PDF

50. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

Author

Pardanani, Animesh, Harrison, Claire, Cortes, Jorge E., Cervantes, Francisco, Mesa, Ruben A., Milligan, Donald, Masszi, Tamás, Mishchenko, Elena, Jourdan, Eric, Vannucchi, Alessandro M., Drummond, Mark W., Jurgutis, Mindaugas, Kuliczkowski, Kazimierz, Gheorghita, Emanuil, Passamonti, Francesco, Neumann, Frank, Patki, Abhay, Gao, Guozhi, and Tefferi, Ayalew

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results